

Title: Drug Development and Approval in the Age of Molecular Targeting and “Precision” Therapy



Speaker

Bruce A. Chabner, M.D.

Director of Clinical Research Cancer Center, Massachusetts General Hospital, Boston Massachusetts



Chairman

Kiyohiko Hatake, M.D., Ph.D.

Chief, Department of Hematology, Cancer Institute Hospital, Japanese Foundation for Cancer Research (JFCR), Japan

Bruce A. Chabner, M.D.

EDUCATION:

1961	BA Summa cum laude	Biology	Yale College
1965	MD Cum laude	Medicine	Harvard Medical School

FACULTY ACADEMIC APPOINTMENTS:

1995-	Professor of Medicine	Medicine	Harvard Medical School
1999-2002	Adjunct Professor	Institute of Health Professions	Massachusetts General Hospital, Boston

APPOINTMENTS AT HOSPITALS/AFFILIATED INSTITUTIONS:

1995-	Physician	Department of Medicine	Massachusetts General Hospital, Boston
1996-2001	Chief Medical Officer		Dana Farber/Partners Cancer Care, Boston
2010-	Director of Clinical Research	Cancer Center	Massachusetts General Hospital, Boston

MAJOR ADMINISTRATIVE LEADERSHIP POSITIONS:

Local

1999-	Associate Director	Clinical Science	Dana-Farber/Harvard Cancer Center, Boston
2010-	Director of Clinical Research	Cancer Center	Massachusetts General Hospital, Boston

National and International

1982-1995	Director	Division of Cancer Treatment	National Cancer Institute
-----------	----------	------------------------------	---------------------------

COMMITTEE SERVICE:

Local

1995-	Chairman, Executive Committee of the Clinical Operations Team		Massachusetts General Hospital
-------	---	--	--------------------------------

NATIONAL AND INTERNATIONAL:

1997-	Advisory Board		Al Amal Cancer Center, Amman, Jordan MGHCC/JFCR
2006-	Member, USA-Japanese Foundation for Cancer Research Collaboration		
2006-2012	Member, National Cancer Advisory Board		National Cancer Institute
2010-	Acting Chair, National Cancer Advisory Board		National Cancer Institute
2010-	Co-Chair, working Group, National Cancer Institute Review, National Cancer Advisory Board		National Cancer Institute

PROFESSIONAL SOCIETIES:

1971-	American Association for Cancer Research	Board of Directors
1982-	American Society for Clinical Investigation	Member
1985-	American Society of Hematology	Member
1985-	Association of American Physicians	Member
1990-	American Clinical and Climatological Association	Member
1991-	American Society of Clinical Oncology	Board of Directors
1995-	Massachusetts Society of Clinical Oncology	Member
2003-	Society for Translational Oncology	Member

EDITORIAL ACTIVITIES:

1994-	Editor-in-Chief	The Oncologist
2001-2006	Senior Editor	Clinical Cancer Research

HONORS AND PRIZES:

1961	Phi Beta Kappa	Yale College
1965	Alpha Omega Alpha	Harvard Medical School
1976	Commendation Medal	Public Health Service
1983	Outstanding Service Medal	Public Health Service
1984	Unit Citation	Public Health Service

1986	Melville Jacobs Award	The American Radium Society
1986	Distinguished Oncologist for 1986	Dayton Oncology Society
1987	Meritorious Service Medal	Public Health Service
1990	Equal Employment Opportunity Special Achievement	National Cancer Institute
1990	Equal Opportunity Officer's Recognition Award	National Cancer Institute
1991	Awarded the flag rank of Rear Admiral	Public Health Service
1993	The Steven Beering Award	Indiana University Awarded for Advancement of Biomedical Science
1994	Distinguished Medal	Public Health Service
1996	Kantor Family Prize	For Cancer Research Excellence
1998	Bruce F. Cain Memorial Award	
2005	Paul Calabresi Award	
2005	Timothy Gee Humanity in Medicine Award	The Lauri Strauss Leukemia Foundation
2006	Bob Pinedo Award	The Society for Translational Oncology
		For Contributions to Improvement in the Care of Cancer Patients (First recipient)
2009	George S. Mitchell Award	Queens University, Belfast For Distinguished Contributions to Cancer Research
2010	Bloch Award	Ohio State University Cancer Center For Distinguished Contributions to Cancer Research

REPORT OF SCHOLARSHIP:

>180 Peer reviewed publications in print or other media
> 280 Reviews, Chapters, Monographs, and Editorials

NARRATIVE REPORT ON CAREER AND RESEARCH INTERESTS:

Dr. Bruce Chabner is a Professor of Medicine at Harvard Medical School and Director of Clinical Research at the Massachusetts General Hospital Cancer Center.

Dr. Chabner graduated *summa cum laude* from Yale College in 1961. He received his M.D. from Harvard University *cum laude* in 1965 following which he completed an internship and junior residency in internal medicine at Peter Bent Brigham Hospital in Boston and a senior residency in internal medicine at Yale-New Haven Medical Center.

Dr. Chabner has had extensive experience in the field of cancer drug discovery and development. After joining the National Cancer Institute (NCI) as a Senior Investigator in the Laboratory of Chemical Pharmacology in 1971, he participated in the training of clinical and research fellows there for the following 24 years, including three years (1976-1979) as Chief of the Clinical Pharmacology Branch; two years (1979-1981) as Director of the Clinical Oncology Program and its fellowship programs in medical, pediatric, radiation, and surgical oncology; and, in 1981, one year as Acting Director, and for 13 years as permanent Director of the Division of Cancer Treatment, NCI.

During the period from 1971 to 1989, he maintained an active laboratory program in cancer pharmacology, focusing on the mechanism of action, and resistance of antifolates and other antimetabolites, and led the development of Taxol. His research contributed significantly to the development of high dose chemotherapy regimens, and to standard therapies for lymphoma.

In 1995, he joined the Massachusetts General Hospital as Clinical Director of its cancer center and Chief of Hematology/Oncology. With the formation of the Dana-Farber/Harvard Cancer Center, he assumed responsibilities as Associate Director for Clinical Sciences of that consortium, which includes the Massachusetts General Hospital, Brigham & Women's Hospital, Dana-Farber Cancer Institute and Beeth Israel Deaconess Medical Center.

He has authored and edited the standard text, Principles and Practice of Cancer Chemotherapy and Biological Response Modifiers, now in its fourth edition, has contributed the chapter on Antineoplastics in Goodman and Gilman's textbook of Pharmacology and has authored chapters for numerous other textbooks of internal medicine, hematology, oncology and pharmacology.

Over the years, Dr. Chabner has received numerous awards, including Phi Beta Kappa, Alpha Omega Alpha, the Public Health Service's Distinguished Service Medal, the Karnofsky Award of the American Society for Clinical Oncology and the Bruce F. Cain Award for Drug Development of the American Association for Cancer Research. In 2006, he was the first recipient of the Bob Pinedo Award for Contributions to Improvement in the Care of Cancer Patients.

Dr. Chabner is a senior editor for the Oncologist and serves on the executive advisory boards for some of the industry's leading innovators in drug development. In 2006, Dr. Chabner received a presidential appointment to the National Cancer Advisory Board at the National Cancer Institute.

IAAO2012 Title of the Talk:

**Drug Development and Approval in the Age of Molecular Targeting and
“Precision” Therapy**